Quantcast
The first installment of our new predictive index shows that dealmakers expect overall M&A to increase, with health care outperforming the overall market READ MORE 

SLIDESHOW

ACG New York Women of Leadership - Entrepreneur Series
Barbara Bradley Baekgaard, founder of Vera Bradley (Nasdaq: VRA), is the latest in a series of entrepreneurs highlighted at ACG New York Women of Leadership events. Photo credit: Robert Blumenfeld

Watercooler

GTCR, Hormel, the Riverside Co-CEOs and Others Win M&A Mid-Market Awards
Amid a slow and challenging year for dealmaking, the winners of Mergers & Acquisitions’ 7th Annual M&A Mid-Market Awards outpaced the competition to grow, innovate and lead the middle market

Roundtable

Financial Services Companies Heat Up M&A Market
Speakers from Flexpoint Ford, Genstar Capital, Baird Capital, Madison Capital Funding and Katten Muchin Rosenman discuss the various factors playing a role in M&A activity within the financial services space

Expert's Corner

Pursuing Pharma Manufacturing
The fragmented pharmaceutical manufacturing industry provides plenty of opportunities for private equity investors, says JLL Partners founder Paul Levy

Today's Transactions:Gilead Sciences Buys YM BioSciences for $510M

The target has been developing a medication to treat myelofibrosis, a bone marrow disorder

Gilead Sciences Inc. (Nasdaq: GILD) will acquire YM BioSciences Inc. (NYSE: YMI) for about $510 million.

The deal amounts to about $2.95 per share.

YM is in the testing phases for a medication that could help patients with myelofibrosis, a bone marrow disorder. The disorder causes bone marrow to be replaced by scar tissue, which makes it difficult for the bone marrow to produce blood cells, which can lead to anemia, low blood-platelet count and spleen enlargement.

Foster City, Calif.-based Gilead is a biopharmaceutical company that commercializes and develops medications.

Other recent pharmaceutical deals include Pernix Therapeutics Holdings Inc.’s (NYSE: PTX) purchase of Somaxon Pharmaceuticals Inc. (Nasdaq: SOMX) in a $25 million all-stock deal, Nuron Biotech’s acquisition of vaccine Meningitec, and Pfizer Inc.’s (NYSE: PFE) NextWave Pharmaceuticals Inc. purchase.

 

For more information on related topics, visit the following: